ISSN 2410-7751 (Print)
ISSN 2410-776X (Online)
Biotechnologia Acta Т. 15, № 5, 2022
P. 41-46. Bibliography 12, Engl.
UDC: 57.088.2
https://doi.org/10.15407/biotech15.05.041
APPROBATION OF CALIX[4]ARENE AS AN ANTITHROMBOTIC AGENT IN VIVO IN VIVO
V. A. Didkivskyi 1, A. O. Pavlenko 1, 2
1 Palladin Institute of biochemistry of the National Academy of Sciences of Ukraine, Kyiv
2 ESC “Institute of biology and medicine”of Taras Shevchenko National University of Kyiv, Ukraine
Intravascular thrombosis is one of the main causes of mortality in the working-age population of the world. There are no antthrombotic drugs that act directly on the final stage of thrombosis – fibrin polymerization. However, a new compound of the calix[4]arene series, calix[4]arene C-145, which directly interacts with the fibrin polymerization site ‘A-knob’ thus blocking formation of polymeric fibrin and preventing thrombosis.
So, the purpose of this work was to study the calix[4]arene C-145 series as antithrombotic agents in vivo using different animals and types of administration.
Materials and methods. Laboratory animals (rats, mice and rabbits) were used for C-145 testing in vivo. Activated partial thromboplastin time and platelet aggregation were measured to determine the anticoagulant action after intravenous or per os administration.
Results. Per os way of administration was selected as the optimal one. We showed the substantial prolongation of clotting time in APTT test that was observed starting from the 2nd hour after the per os administration, reached the maximum on 6th hour and eliminated in 24 hours. The effect of C-145 on platelets reached maximum on 4-6 hours and eliminated in 12 hours.
Conclusions. C-145 was proven to be prospective antithrombotic drug that can be administered per os. Further investigations must be focused on the study of C-145 pharmacodynamics and metabolism. Such data would allow fast implementation of the tested compound into practice.
Key words: calix[4]arene, blood plasma, platelets, thrombosis, blood coagulation, noncovalent complex.
© Palladin Institute of Biochemistry of National Academy of Sciences of Ukraine, 2022
References
1. Chernyshenko V.O. Mechanisms of intravascular and extravascular blood clotting: fundamental studies for clinical practice. Visn. Nac. Acad. Nauk Ukr. 2019, 4, 50‒56. https://doi.org/10.15407/visn2019.04.050
2. Chernyshenko V. O, Lugovska N. E. Molecular mechanisms of intravascular inhibition and stimulation of extravascular thrombosis. Biotechnologia Acta. 2021, 14(6), pp. 5‒22. https://doi.org/10.15407/biotech14.06.005
3. Asfari M. Z., Bohmer V., Harrowfield J., Vicens J. (eds). Calixarenes 2001. Kluwer academic Publishers. 2001, 3‒684. https://doi.org/10.1007/0-306-47522-7
4. Komisarenko S. V., Kosterin S. O., Lugovskoy E. V., Kalchenko V. I. Calixarene methylene bisphosphonic acids as promising effectors of biochemical processes. Ukr. Biochem. J. 2013, 85(6), 106‒128. https://doi.org/10.15407/ubj85.06.106
5. Lugovskoy E. V., Gritsenko P. G., Koshel T. A., Koliesnik I O., Cherenok S. O., Kalchenko O. I., Kalchenko V. I., Komisarenko S. V. Calix[4]arene methylenebisphosphonic acids as inhibitors of fibrin polymerization. FEBS J. 2011, 278(8), 1244‒51. https://doi.org/10.1111/j.1742-4658.2011.08045.x
6. Chernyshenko V. O., Korolova D. S., Dosenko V. Е., Pashevin D. O., Kalchenko V. I., Pirogova L. V., Chernyshenko T. M., Lugovska O. E., Kravchenko N. А., Makogonenko Y. M., Lugovskoy E. V., Komisarenko S. V. Calix[4]arene C-145 Effects on Plasma Haemostasis. Pharmaceutica Analytica Acta. 2015, 6(8), 1‒5. https://doi.org/10.4172/2153-2435.1000406
7. Rodik R. V., Boyko V. I., Kalchenko V. I. Calixarenes in bio-medical researches. Current Medicinal Chemistry. 2009, 16(13), 1630‒1655. https://doi.org/10.2174/092986709788186219
8. Bansal S, Sangha KS, Khatri P. Drug treatment of acute ischemic stroke. Am J Cardiovasc Drugs. 2013, 13(1), 57‒69. https://doi.org/10.1007/s40256-013-0007-6
9. Alsenaidy M.A., Kazi M., Ahmad M.Z. Advances in Oral Drug Delivery. Sec. Translational Pharmacology. 2021, 12, 618411. https://doi.org/10.3389/fphar.2021.618411
10. Homayun B., Lin X., Choi H.J. Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals. Pharmaceutics. 2019, 11(3), 29. https://doi.org/10.3390/pharmaceutics11030129
11. Hartmann S., Biliouris K., Lesko L.J., Nowak-Göttl U., Trame M.N. Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy. Front Pharmacol. 2020, 14(11), 1041. https://doi.org/10.3389/fphar.2020.01041
12. Chernyshenko V., Pirogova L., Didkivskyi V., Cherenok S., Dosenko V., Pashevin D., Kalchenko V., Mаkogonenko E., Lugovskoy E. Effects of calix[4]arene C-145 on overall haemostatic potential of blood plasma in vitro and in vivo. Journal of International Research in Medical and Pharmaceutical Sciences. 2016. 10(3), 146‒151.